Diabetic neuropathy: Therapies on the horizon

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 9, 2009, Pages 1137-1145

  Mahmood, Danish ^a   Singh, Bhulan Kumar ^a   Akhtar, Mohammad ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Diabetic neuropathy; Non immunosuppressive immunophilin ligand; Poly(ADP ribose) polymerase inhibitors

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; AMINOGUANIDINE; C PEPTIDE; CALCITONIN GENE RELATED PEPTIDE; CORTICOSTEROID; CYCLOSPORIN; EPALRESTAT; ERYTHROPOIETIN; FIDARESTAT; FK 1706; GLUTAMATE CARBOXYPEPTIDASE II INHIBITOR; GPI 15427; IMMUNOGLOBULIN; IMMUNOPHILIN; INOSITOL; ISLET NEOGENESIS ASSOCIATED PROTEIN PEPTIDE; LEVACECARNINE; LYCOPENE; MELOXICAM; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; RANIRESTAT; RUBOXISTAURIN; SORBINIL; SUBSTANCE P; SUBSTANCE P ANTAGONIST; SYNTHETIC PEPTIDE; THIOCTIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; ANTIOXIDANT; ENZYME INHIBITOR; SIGNAL PEPTIDE;

ANEMIA; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG EFFICACY; FLU LIKE SYNDROME; GENE THERAPY; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; MONONEUROPATHY; MONONEUROPATHY MULTIPLEX; NERVE CELL; NERVE FIBER; NERVE INJURY; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PAIN; PALLIATIVE THERAPY; PARESTHESIA; PATHOGENESIS; RADICULOPATHY; REVIEW; SENSORY DYSFUNCTION; SIGNAL TRANSDUCTION; STOMACH DISEASE; ANIMAL; BIOLOGICAL MODEL; CLASSIFICATION;

ANIMALS; ANTIOXIDANTS; CLINICAL TRIALS AS TOPIC; DIABETIC NEUROPATHIES; ENZYME INHIBITORS; GENE THERAPY; HUMANS; IMMUNOPHILINS; IMMUNOTHERAPY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, BIOLOGICAL;

EID: 85047682290     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.09.0002     Document Type: Review

References (75)

1. Boulton AJM et al. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet Med 1998; 15: 508-514.
2. Vinik AI et al. Epidemiology of the complications of diabetes. In: Leslie RDG, Robbins DC, eds. Diabetes: Clinical Science in Practice. Cambridge: Cambridge University Press, 1995: 221-287.
3. Vinik AI, Mehrabyan A. Understanding diabetic neuropathies. Emerg Med 2004; 5: 39-44.
4. Young MJ et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36: 1-5.
5. Khwaja GA, Chaudhry N. Current and emerging therapies for painful diabetic neuropathies. J Ind Acad Clin Med 2007; 8: 53-64.
6. Gordois A et al. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003; 26: 1790-1795.
7. Thomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes 1997; 46: S54-S57.
8. Boulton AJ et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 956-962.
9. Greene DA et al. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 1999; 53: 580-591.
10. Ahmed N. Advanced glycation endproducts - role in pathology of diabetic complications. Diabetes Res Clin Pract 2005; 67: 3-21.
11. Toth C et al. Receptor for advanced glycation end products (RAGE) and experimental diabetic neuropathy. Diabetes 2008; 57: 1002-1017.
12. Wada R, Yagihashi S. Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Ann NY Acad Sci 2005; 1043: 598-604.
13. Ziegler D et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006; 29: 2365-2370.
14. Meier M, King GL. Protein kinase C activation and its pharmacological inhibition in vascular disease. Vas Med 2000; 5: 173-185.
15. Llewelyn JG. The diabetic neuropathies: types, diagnosis and management. J Neurol Neurosurg Psychiatry 2003; 74: 15-19.
16. Chattopadhyay M. HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy. Gene Ther 2005; 12: 1377-1384.
17. Kusano KF et al. Sonic hedgehog induces arteriogenesis in diabetic vasa nervorum and restores function in diabetic neuropathy. Arterioscler Thromb Vasc Biol 2004; 4: 2102-2107.
18. Kato N et al. Nonviral gene transfer of human hepatocyte growth factor improves streptozotocin-induced diabetic neuropathy in rats. Diabetes 2005; 54: 846-854.
19. Diemel et al. Depletion of substance P and calcitonin generelated peptide in sciatic nerve of rats with experimental diabetes: effects of insulin and aldose reductase inhibition. Neurosci Lett 1992; 137: 253-256.
20. Tomlinson DR et al. Neurotrophins and peripheral neuropathy. Philos Trans R Soc Lond B Biol Sci 1996; 351: 455-462.
21. Apfel SC, Kessler JA. Neurotrophic factors in the therapy of peripheral neuropathy. Baillieres Clin Neurol 1995; 4: 593-606.
22. Calcutt NA et al. Growth factors as therapeutics for diabetic neuropathy. Curr Drug Targets 2008; 9: 47-59.
23. Ogawa T et al. Intravenous immunoglobulin therapy for diabetic amyotrophy. Intern Med 2001; 40: 349-352.
24. Cocito D et al. Intravenous immunoglobulin as first treatment in diabetics with concomitant distal symmetric axonal polyneuropathy and CIDP. J Neurol 2002; 249: 719-722.
25. Sharma KR et al. Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy. Arch Neurol 2002; 59: 751-757.
26. Siemionow M, Demir Y. Diabetic neuropathy: pathogenesis and treatment. J Reconstr Microsurg 2004; 20: 241-252.
27. Chung SS, Chung SK. Aldose reductase in diabetic microvascular complications. Curr Drug Targets 2005; 6: 475-486.
28. Matsumoto T et al. Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats. J Pharmacol Sci 2008; 107: 231-237.
29. Bril V, Buchanan RA. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2006; 29: 68-72.
30. Oates PJ. Aldose reductase, still a compelling target for diabetic neuropathy. Curr Drug Targets 2008; 9: 14-36.
31. Hotta N et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative aldose reductase inhibitordiabetes complications trial. Diabetes Care 2006; 29: 1538-1544.
32. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002; 54: 375-429.
33. Pacher P. Poly(ADP-ribose) polymerase inhibition as a novel therapeutic approach against intraepidermal nerve fiber loss and neuropathic pain associated with advanced diabetic neuropathy: a commentary on "PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy". Free Radic Biol Med 2008; 44: 969-971.
34. Yamazaki S et al. FK1706, a novel non immunosuppressive immunophilin ligand, modifies the course of painful diabetic neuropathy. Neuropharmacology 2008; 55: 1226-1250.
35. Polonsky KS et al. Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest 1986; 77: 98-105.
36. Zierath JR et al. Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM. Diabetologia 1996; 39: 1180-1189.
37. +-ATPase activity in synergism with neuropeptide Y. Diabetologia 1996; 39: 199-205.
38. Kamiya H et al. C-peptide prevents nociceptive sensory neuropathy in type 1 diabetes. Ann Neurol 2004; 56: 827-835.
39. Rosenberg L et al. A pentadecapeptide fragment of islet neogenesis associated protein increases beta-cell mass and reverses diabetes in C57BL/6J mice. Ann Surg 2004; 240: 875-884.
40. Tam J et al. INGAP peptide improves nerve function and enhances regeneration in streptozotocin-induced diabetic C57BL/6 mice. FASEB J 2005; 8: 1767-1769.
41. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859-866.
42. Nakamura J et al. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999; 48: 2090-2095.
43. Cotter MA et al. Effects of protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes. Clin Sci (Lond) 2002; 103: 311-321.
44. Obrosova I et al. Taurine counteracts oxidative stress and nerve growth factor deficit in early experimental diabetic neuropathy. Exp Neurol 2001; 172: 211-219.
45. Vinik AI et al. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clin Ther 2005; 27: 1164-1180.
46. Sima AAF et al. Primary preventive and secondary interventional effects of acetyl-L-carnitine on diabetic neuropathy in the BB/W-rat. J Clin Invest 1996; 97: 1900-1907.
47. Sima AF et al. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy. Diabetes Care 2005; 28: 96-101.
48. Ohsawa M et al. Preventive effect of acetyl-L-carnitine on the thermal hypoalgesia in streptozotocin-induced diabetic mice. Eur J Pharmacol 2008; 588: 213-216.
49. Khuhad A et al. Lycopene attenuates thermal hypoalgesia in a diabetic mouse model of neuropathic pain. Eur J Pain 2008; 12: 624-632.
50. Packer L et al. Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition 2001; 17: 888-895.
51. Gooch C, Podwall D. The diabetic neuropathies. Neurologist 2004; 10: 311-322.
52. Sharma S et al. Resveratrol, a polyphenolic phytoalexin attenuates thermal hyperalgesia and cold allodynia in STZ-induced diabetic rats. Indian J Exp Biol 2006; 44: 566-569.
53. Kumar A et al. Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy. Life Sci 2007; 80: 1236-1244.
54. Sharma S et al. Effect of resveratrol, a polyphenolic phytoalexin, on thermal hyperalgesia in a mouse model of diabetic neuropathic pain. Fund Clin Pharmacol 2007; 21: 89-94.
55. Ziegler D et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN study). Diabetologia 1995; 38: 1425-1433.
56. Ziegler D et al. Effects of treatment with the antioxidant alphalipoic acid on cardiac autonomic neuropathy in NIDDM patients: a 4-month randomized controlled multicenter trial (DEKAN study). Deutsche kardiale autonome neuropathie. Diabetes Care 1997; 20: 369-373.
57. Ziegler D et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III study group. α-Lipoic acid in diabetic neuropathy. Diabetes Care 1999; 22: 1296-1301.
58. Cameron NE, Cotter MA. Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes. Diabetes Res Clin Pract 1999; 45: 137-146.
59. Hounsom L et al. A lipoic acid-gamma linoleic acid conjugate is effective against multiple indices of experimental diabetic neuropathy. Diabetologia 1998; 41: 839-843.
60. Biessels GJ et al. The effects of gamma-linoleic acid-alphalipoic acid on functional deficits in the peripheral and central nervous system of streptozotocin-diabetic rats. J Neurol Sci 2001; 182: 99-106.
61. Zang M et al. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor deficient mice. Diabetes 2006; 55: 2180-2191.
62. Chen WP et al. Resveratrol enhances insulin secretion by blocking K(ATP) and K(V) channels of beta cells. Eur J Pharmacol 2007; 568: 269-277.
63. Sun Y et al. Effectiveness of vitamin B12 on diabetic neuropathy: systematic review of clinical controlled trials. Acta Neurol 2005; 14: 48-54.
64. Singh et al. Alpha-lipoic acid supplementation and diabetes. Nutrition Rev 2008; 66: 646-657.
65. Nagai A et al. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 2001; 60: 386-392.
66. Lipton SA. Erythropoietin for neurologic protection and diabetic neuropathy. N Engl J Med 2004; 350: 2516-2517.
67. Sindrup SH et al. The NK(1)-receptor antagonist TKA731 in painful diabetic neuropathy: a randomised, controlled trial. Eur J Pain 2006; 10: 567-571.
68. Pop-Busui R et al. Dissection of metabolic, vascular and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration. Diabetes 2002; 51: 2619-2628.
69. Vinik AI, Mehrabyan A. Diabetic neuropathies. Med Clin North Am 2004; 88: 947-999.
70. Miyauchi et al. Slowing of peripheral nerve conduction was ameliorated by amino guanidine in streptozotocin induced diabetic rats. Eur J Endocrinol 1996; 134: 467-473.
71. Schmidt RE et al. Effect of aminoguanidine on the frequency of neuroaxonal dystrophy in superior mesenteric sympathetic autonomic ganglia of rats with STZ-induced diabetes. Diabetes 1996; 45: 284-290.
72. Wada R et al. Effects ofOPB-9195, anti-glycation agent, on experimental diabetic neuropathy. Eur J Clin Invest 2001; 31: 513-520.
73. Yamagishi SI, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharmaceut Des 2005; 11: 2279-2299.
74. Bolton et al. Randomized clinical trial of an inhibitor of formation of AGE products in diabetic neuropathy. Am J Nephrol 2004; 24: 32-40.
75. Zhang W et al. GCPII (NAALADase) inhibition prevents longterm diabetic neuropathy in type 1 diabetic BB/W or rats. J Neurol Sci 2002; 194: 21-28.